Amgen
Amgen didn’t disrupt pharma — it proved that cloning one human gene at a time could build a billion-dollar company.
Biography
A life shaped into a narrative it did not have while being lived.
- 4
- in business
- 9:50
- average
- 39 min
- in total
- 25
- across the network
All briefs
Genmab
Jan van de Winkel · 1998
Genmab is a platform biotech — not a drug developer — built around two licensed and proprietary antibody generation methods. Its value is in reducing discovery risk and time, not in owning clinical or commercial outcomes.
Regeneron Pharmaceuticals
George Yancopoulos · 1988
Regeneron is a biotech firm whose core innovation — the receptor trap — emerged from neurobiology, not pharmacology. It monetises that science via high-value partnerships and outsized government contracts, not broad platform dominance. Its success depends less on internal scale than on strategic leverage of public R&D funding.
Serum Institute of India
The world’s largest vaccine maker by volume is not a tech disruptor — it’s a high-volume, low-margin public health utility run as a private company.